Loading the session
Loading the session
Loading instrument
$7.13
−3.91%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:14 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +1.5% (SPY −1.6%, XLV +13.5%). 3 months: −11.7% (SPY −0.4%, XLV +15.5%). 1 year: −22.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ARVN, SPY and XLV · as of 4 Nov 2026
5.6M shares were sold short at the 15 Oct 2026 settlement, 8.7% of the 64.5M shares outstanding; covering them would take 8.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Closed at $7.42 on 4 Nov 2026: 48.9% below the 52-week high of $14.51 (10 Mar 2026) and 10.1% above the low of $6.74 (14 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
The 4 Nov 2026 close of $7.42 was 7.0% below its 50-day average ($7.98) and 22.8% below its 200-day average ($9.61). It has closed below the 200-day for 127 sessions, since 6 May 2026. The 50-day average crossed below the 200-day on 21 May 2026, 115 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
4 Nov 2026 volume of 1.2M shares was 1.6× the average of the 30 sessions before it (791.4K), as the price rose 4.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
May 1, 2025
−24.84%March 11, 2025
−52.73%December 6, 2023
+30.77%